SCHEMBL2564592

SCHEMBL2564592

Clc1ccc(-c2cn3c(n2)sc2ccccc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.56
TP53 P04637 5/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
MAPT P10636 4/20 0.52
RAB9A P51151 3/20 0.52
LMNA P02545 2/20 0.52
TSHR P16473 1/20 0.52
ATM Q13315 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ADORA2A P29274 1/20 0.49
FLT3 P36888 1/20 0.48
NPC1 O15118 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
APP P05067 1/20 0.45
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
F2RL3 Q96RI0 1/20 0.44
MET P08581 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL84416 0.88 RAB9A (0.64) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL11013680 0.86 THRB (0.57) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL9569335 0.85 THRB (0.53) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL10806421 0.85 MAPT (0.52) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL9569337 0.85 MAPT (0.52) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL74089 0.85 MAPT (0.52) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL13650900 0.85 LMNA (0.55) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL5909037 0.84 LMNA (0.53) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL10814270 0.82 THRB (0.48) THRBTP53SMN1; SMN2MAPTRAB9A
SCHEMBL11012079 0.82 THRB (0.48) THRBTP53SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11559518-B2 Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound ER STRESS RESEARCH INSTITUTE, INC. (JP) 2023-01-24 US disclosed
US-20210386715-A1 ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND ER STRESS RESEARCH INSTITUTE, INC. (JP) 2021-12-16 US disclosed
WO-2011132048-A1 HETEROARYL COMPOUNDS AS PDE10A INHIBITORS GLENMARK PHARMACEUTICAL S.A. (CH) 2011-10-27 WO disclosed
US-4497817-A ANTIALLERGENS-IMMUNOSUPPRESSIVE AGENTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1985-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11559518-B2 Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound HSPA5, DNAJC10, ERP44 THRB 1454/4885TP53 1281/4885SMN1; SMN2 2693/4885
US-20210386715-A1 ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND DNAJC10, HSPA5, ERP44 THRB 2208/4885TP53 1668/4885SMN1; SMN2 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.